SCHEMBL2473732

SCHEMBL2473732

C=CCC(N)c1ccccc1-c1cc(F)ccc1C

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDCD1LG2 Q9BQ51 2/20 0.36
CD274 Q9NZQ7 2/20 0.36
CTSA P10619 3/20 0.33
MAPK14 Q16539 3/20 0.32
KCNA5 P22460 1/20 0.32
NISCH Q9Y2I1 1/20 0.31
PLA2G7 Q13093 1/20 0.31
PDE2A O00408 1/20 0.31
PDE10A Q9Y233 1/20 0.31
ABL1 P00519 1/20 0.31
FLT3 P36888 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
CYP2D6 P10635 1/20 0.30
HPGD P15428 1/20 0.30
MAPK1 P28482 1/20 0.30
CYP2C19 P33261 1/20 0.30
GRM5 P41594 1/20 0.30
LRRK2 Q5S007 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477950 0.84 PDCD1LG2 (0.41) PDCD1LG2CD274PLA2G7CYP3A4
SCHEMBL2474504 0.80 ALOX5AP (0.38) PDCD1LG2CD274CTSA
SCHEMBL2471466 0.79 PTGS2 (0.38) PDCD1LG2CD274MAPK14ABL1CYP2C19
SCHEMBL2474346 0.78 PDCD1LG2 (0.36) PDCD1LG2CD274
SCHEMBL2477497 0.78 PDCD1LG2 (0.39) PDCD1LG2CD274CYP2C19
SCHEMBL8995483 0.77 ESR1 (0.41) PDCD1LG2CD274CYP3A4CYP2D6CYP2C19
Hydrochloric Acid SCHEMBL2473520 0.73 PDCD1LG2 (0.46) PDCD1LG2CD274
SCHEMBL2476189 0.73 PDCD1LG2 (0.39) PDCD1LG2CD274
SCHEMBL6709980 0.73 ESR1 (0.38) PDCD1LG2CD274
SCHEMBL7566094 0.73 ESR1 (0.38) PDCD1LG2CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 PDCD1LG2 3624/4885CD274 2894/4885CTSA 1324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.